erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.
暂无分享,去创建一个
B Fisher | S. Paik | J. Bryant | D. Wickerham | N. Wolmark | B. Fisher | E. Fisher | M. Lippman | E. Tan-chiu | E R Fisher | N Wolmark | D L Wickerham | E Tan-Chiu | J Bryant | S Paik | C Park | D Hyams | M E Lippman | C. Park | S. Paik | N. Wolmark | D. Hyams | C. Park | Edwin R. Fisher
[1] L. Norton,et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.
[2] A. Gazdar,et al. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. , 1996, Cancer research.
[3] G. Wishart,et al. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. , 1993, European journal of cancer.
[4] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[5] M. Lippman,et al. Quantification of erbB-2/neu levels in tissue. , 1991, Methods in enzymology.
[6] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[7] C. Osborne,et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] C. Arteaga,et al. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. , 1994, Cancer research.
[9] N. Ibrahim,et al. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. , 1995, Journal of the National Cancer Institute.
[10] K. Chew,et al. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer , 1997, Oncogene.
[11] A. Harris,et al. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. , 1993, Oncogene.
[12] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] G. Wishart,et al. Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 , 1993 .
[14] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[15] V. Chinchilli,et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Anna L. Brown,et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] C. Redmond,et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Kononen,et al. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. , 1996, The American journal of pathology.
[19] L. Norton,et al. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. , 1997, Oncology.